
|Articles|January 19, 2022
Daily Medication Pearl: Brimonidine Ophthalmic Solution (Alphagan P)
Author(s)Saro Arakelians, PharmD
Brimonidine ophthalmic solution (Alphagan P) is indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Advertisement
Medication Pearl of the Day: Brimonidine ophthalmic solution (Alphagan P)
Indication: Brimonidine ophthalmic solution (Alphagan P) is an alpha-adrenergic receptor agonist indicated for the reduction of elevated intraocular pressure (IOP) in patients with open-angle glaucoma or ocular hypertension.
Insight:
- Dosing: One drop in the affected eye(s), 3 times daily, approximately 8 hours apart.
- Dosage forms: Solution containing 1 or 1.5 mg/mL brimonidine tartrate.
- Adverse events: Most common adverse reactions occurring in approximately 5% to 20% of patients receiving brimonidine ophthalmic solution (0.1%-0.2%) included allergic conjunctivitis, burning sensation, conjunctival folliculosis, conjunctival hyperemia, eye pruritus, hypertension, ocular allergic reaction, oral dryness, and visual disturbance.
- Mechanism of action: Alphagan P is a relatively selective alpha-2 adrenergic receptor agonist with a peak ocular hypotensive effect occurring at 2 hours post-dosing.
- Manufacturer: Allergan
Sources:
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
Men Face Higher Odds of Later-Stage Diagnosis Across 20 Cancer Types
2
FDA Accepts NDA for AD109 to Treat of Adults With Obstructive Sleep Apnea
3
Investigational mRNA Flu Vaccine Broadens Antibody Defenses, Sustains Immune "Training Hub" Longer Than Standard Shot
4
FDA Approves Enlicitide, the First Oral PCSK9 Inhibitor for High Cholesterol
5






































































































